Is Trump Going to Kill the GLP-1 Cash Cow?

Novo Nordisk (NVO) and Eli Lilly (LLY), leading the GLP-1 drug market with over $20 billion in sales, experienced significant stock declines, erasing more than $20 billion in combined market value, following former President Trump's pledge to drastically reduce GLP-1 drug prices. This potential policy intervention, which could cut monthly costs from approximately $1,000 to $150, threatens the companies' high 40% gross margins and could severely impact future revenues, R&D funding, and long-term growth, although some analysts view the immediate market sell-off as potentially overdone.

Analysis

Novo Nordisk (NVO) and Eli Lilly (LLY) have established dominant positions in the GLP-1 drug market, generating over $20 billion in sales in 2024 and achieving record profits, with NVO's GLP-1s accounting for over 60% of its revenue. This success has funded significant expansion, including NVO's $4.1 billion U.S. manufacturing plant and LLY's $6.5 billion Houston facility. However, former President Trump's pledge to drastically cut GLP-1 prices, potentially to $150 monthly from current $1,000 list prices, triggered an immediate market reaction.

Shares of NVO fell over 4% and LLY dropped 2.6% in morning trading, erasing more than $20 billion in combined market value. This proposed price reduction threatens the companies' high 40% gross margins, which are crucial for recouping $2-3 billion in R&D investments per product. JPMorgan estimates a 50% price cut could trim NVO's annual profits by $5 billion and potentially reduce LLY's Zepbound sales by 30-40% short-term, impacting pipeline funding.

Despite the immediate sell-off, analysts like BMO Capital suggest the reaction may be "overdone," noting that insured patients already pay as little as $25 monthly due to rebates. Both NVO and LLY have also preemptively cut prices to expand access. The article suggests Trump's rhetoric often leads to more nuanced negotiations, and the long-term outlook, particularly for LLY, remains positive, though future growth rates could be capped at 10-15% annually from 30% currently.

Key Decisions for Investors

• Monitor policy developments closely, particularly regarding drug pricing legislation and the upcoming election cycle's potential impact on pharmaceutical regulations.
• Evaluate the potential long-term impact of reduced pricing power on NVO and LLY's R&D pipelines and future growth rates, considering patent expiry in 2031-2032.
• Assess current valuations in light of potential policy risks versus the strong underlying demand and existing market leadership, especially for LLY given its positive long-term outlook.